Bernasconi F, Galli F, Ersettigh G, Arienti S
Divisione di Ostetricia e Ginecologia, Ospedale di Desio (Milano), Regione Lombardia, USSL n. 63.
Minerva Ginecol. 1995 Apr;47(4):147-54.
The authors have investigated the efficacy of i.m. therapy with interferon (IFN) in the treatment of female genital condylomatosis: 94 consecutive patients underwent a randomized therapy with two different IFNs: beta-IFN and alpha-2A-IFN (3,000.000 UI i.m. on alternate days for 4 weeks). A total and/or partial response was observed in 76.5% of cases (72/94). Observed response was unrelated with used IFN, independently of type and seat of treated lesion. There was only an important difference between the two treatments in the incidence of side-effects and drop-out (31% and 6.3% with alpha-2A-IFN and 14.8% and 2.1% with beta-IFN). Systemic therapy with IFN is a good alternative to destructive techniques in the treatment of HPV-associated pathology of female lower genital tract.
作者研究了肌内注射干扰素（IFN）治疗女性尖锐湿疣的疗效：94例连续患者接受了两种不同干扰素的随机治疗：β-干扰素和α-2A-干扰素（300万国际单位，隔日肌内注射，共4周）。76.5%的病例（72/94）观察到完全和/或部分缓解。观察到的缓解与所用干扰素无关，与治疗病变的类型和部位无关。两种治疗在副作用发生率和退出率方面仅有显著差异（α-2A-干扰素分别为31%和6.3%，β-干扰素分别为14.8%和2.1%）。干扰素全身治疗是治疗女性下生殖道HPV相关病变时替代破坏性技术的良好选择。
